GlassScriptPhysician profile
Tami Michele Secor
NPI 1336185354
$13,949.95
in general payments reported to CMS, 2019-2025
48 companies · $1,734 in 2025
The $1,734 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,201 · 2020: $1,446 · 2021: $1,810 · 2022: $1,937 · 2023: $2,866 · 2024: $2,956 · 2025: $1,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,555.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,217.53 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $2,094.79 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,172.15 | 2019-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $1,022.96 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,007.63 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $703.61 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $600.31 | 2019-2025 | Spravato |
| Axsome Therapeutics, INC. | $552.23 | 2023-2025 | Auvelity, Symbravo |
| Astellas Pharma US INC | $398.91 | 2019-2025 | Veozah, Myrbetriq |
| Phathom Pharmaceuticals, INC. | $373.46 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $360.22 | 2023-2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $347.51 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $340.86 | 2019-2025 | Trintellix |
| Glaxosmithkline, LLC. | $336.01 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $255.45 | 2020-2024 | Capvaxive, Gardasil 9, Gardasil |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tami Secor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.